NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company itself and of all its subsidiaries due to termination of mandates. This transition is part of our ongoing commitment to strong corporate governance and effective leadership.
Nerviano Medical Sciences S.r.l.
Changes to the Board of Directors
We would like to inform you of the following appointments to our Board of Directors:
- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke
- Sidney Dung
- Serena Alvino
- Tiziano Lazzaretti
These appointments follow the conclusion of the mandates of the following directors:
- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke
Changes to Statutory Auditors
Additionally, we are pleased to announce the appointment of new statutory auditors:
- Andrea Piermartini Rosi (Chairman)
- Annalisa De Palma
- Massimo Gabelli
These appointments follow the conclusion of the mandates of the following auditors:
- Mario Tagliaferri (Chairman)
- Stefano Sacchi
- Massimo Venuti
We extend our sincere gratitude to the outgoing directors and auditors for their dedicated service and valuable contributions to NMS Group and its subsidiaries. We welcome the new members and are confident that their expertise will significantly benefit the company.
Link PR:20240528-NMS SRL new BoD and Statutory Auditors
Read more: about the Board of Directors and Statutory Auditors of all NMS Group companies please click the link below:
https://www.nmsgroup.it/governance-and-ethics-compliance/
